### 2.2.1 In vitro and physico-chemical data

A literature search was performed to collect available information on physico-chemical properties of fluvoxamine ([Table 1](#Table 1)).

| **Parameter**                     | **Unit** | **Value**       | Source                            | **Description**                                              |
| :-------------------------------- | -------- | --------------- | --------------------------------- | ------------------------------------------------------------ |
| MW<sup>+</sup>                    | g/mol    | 318.33          | [DrugBank DB00176](#5-references) | Molecular weight of free base. Dose of commercial product usually refers to amount of fluvoxamine maleate â€“ conversion factor is 0.733 |
| pK<sub>a,base</sub><sup>+</sup>   |          | 9.16            | [Alqahtani 2016](#5-references)   | Basic dissociation constant                                  |
| Solubility (pH)<sup>+</sup>       | mg/mL    | 0.06<br />(7.4) | [PubChem 9560989](#5-references)  | Aqueous Solubility                                           |
| logP<sup>+</sup>                  |          | 3.38            | [Alqahtani 2016](#5-references)   | Partitioning coefficient                                     |
| fu<sup>+</sup>                    | %        | 23              | [Alqahtani 2016](#5-references)   | Fraction unbound in plasma                                   |
| K<sub>i</sub> CYP1A2<sup>+</sup>  | nmol/L   | 2.97            | [Iga 2016](#5-references)         | CYP1A2 inhibition constant                                   |
| K<sub>i</sub> CYP2C19<sup>+</sup> | nmol/L   | 3.6             | [Iga 2016](#5-references)         | CYP2C19 inhibition constant (omeprazole as substrate)        |
| K<sub>i</sub> CYP2C19<sup>+</sup> | nmol/L   | 2.6             | [Iga 2016](#5-references)         | CYP2C19 inhibition constant (s-mephenytoin as substrate)     |

**Table 1:**<a name="Table 1"></a> Physico-chemical and *in-vitro* metabolization properties of fluvoxamine extracted from literature. *<sup>+</sup>: Value used in final model*

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on fluvoxamine in adults. Data used for model development and validation is listed in [Table 2](#Table 2).

| **Source**           | **Route** | **Dose [mg]/**  **Schedule \*** | **Pop.**     | **Age [yrs] (mean)** | **Weight [kg] (mean)** | **Sex** | **N** | **Form.** | **Comment**                       |
| -------------------- | --------- | ------------------------------- | ------------ | -------------------- | ---------------------- | ------- | ----- | --------- | --------------------------------- |
| [Carillo 1996](#5-references) | p.o.      | 50                              | HV           | -                    | -                      | m/f     | 5     | e.c. Tab  | Non-smoking  EM / Smoking EM  |
| [Carillo 1996](#5-references)<sup>+</sup> | p.o. | 50 | HV | - | - | m/f | 5 | e.c. Tab | Non-smoking PM |
| [Spigset 1997](#5-references)<sup>+</sup> | p.o.      | 50                              | HV           | -                    | -                      |         | 5     | e.c. Tab  | PM                                |
| [Spigset 1997](#5-references) | p.o.      | 50                              | HV           | -                    | -                      |         | 5     | e.c. Tab  | EM                                |
| [Iga 2015](#5-references)<sup>+</sup> | i.v. | 50                        | Japanese     | -    | -    | -    | -    | -             | -                                   |
| [Iga 2015](#5-references) | p.o. | 50                        | Japanese     | -    | -    | -    | -    | -             | -                                   |
| [Orlando 2009](#5-references) | p.o. | 50                        | HV           | 35   | 79   | male | 10   | -             | -                                   |
| [Spigset 1998](#5-references)<sup>+</sup> | p.o. | 50 / 100 b.i.d. | HV           | 28.9 | 85.6 | male | 10   | e.c. Tab      | -                                   |
| [Spigset 1998](#5-references) | p.o. | 12.5/ 25 b.i.d. | HV | 28.9 | 85.6 | male | 10 | e.c. Tab | - |
| [DeVries 1993](#5-references)<sup>+</sup> | p.o. | 25 / 50/ 100              | HV           | -    | -    | male | 12   | solution      | -                                   |
| [VanHarten 1994](#5-references) | p.o. | 50                        | HV           | -    | -    | male | 17   | capsule       | -                                   |
| [VanHarten 1991](#5-references) | p.o. | 50                        | HV           | 24   | 73   | m/f  | 12   | e.c. Tab      | With/ without food                  |
| [Kunii 2005](#5-references) | p.o. | 50                        | HV           | 29.7 | 69.3 | m    | 10   | e.c. Tab      | -                                   |
| [Fukasawa 2006](#5-references) | p.o. | 50                        | HV           | 29.6 | 68.3 | m    | 12   | e.c. Tab      | -                                   |
| [Fleishaker 1994](#5-references)<sup>+</sup> | p.o. | 12.5 - 25 - 50 - 100 q.d. | HV           | 32   | 80   | m    | 20   | e.c. Tab      | -                                   |
| [Labellarte 2004](#5-references)<sup>+</sup> | p.o. | 25 / 50 / 100/ 150 b.i.d. | Adole-scents | 14   | 60   | m/f  | 23   | e.c. Tab      | -                                   |
| [Spigset 1997](#5-references) | p.o. | 50                        | HV           | 34.7 | 66.5 | m/f  | 12   | e.c. Tab      | non-smokers / smoker                |
| [FDA_ClinPharmReview LuvoxCR](#5-references)<sup>+</sup> | p.o. | 100      | HV           | -    | -    | -    | 20   | e.c. Tab / CR | -                                   |
| [FDA_ClinPharmReview LuvoxCR](#5-references)<sup>+</sup> | p.o. | 100 q.d. | HV | - | - | - | 20 | e.c. Tab / CR | - |
| [FDA_ClinPharmReview LuvoxCR](#5-references) | p.o. | 200 / 300 q.d. | HV | - | - | - | 20 | e.c. Tab / CR | - |

**Table 2:**<a name="Table 2"></a> Literature sources of clinical concentration data of fluvoxamine used for model development and validation. *e.c.: enteric coated; -: respective information was not provided in the literature source; \*:single dose unless otherwise specified; <sup>+</sup>: Data used for final parameter identification*